Delving into the Latest Updates on Parecoxib Sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamide, parecoxib, Parecoxib sodium (USAN)

+ [8]

Target

COX-2

Mechanism

COX-2 inhibitors(Cyclooxygenase-2 inhibitors)

Therapeutic Areas

Nervous System Diseases

Active Indication

Pain, Postoperative

Inactive Indication

ColicRenal Colic

Originator Organization

Pfizer Inc.

Active Organization

Pfizer Europe MA EEIG

Inactive Organization

Pfizer Inc.

Drug Highest PhaseApproved

First Approval Date

EU (22 Mar 2002),

Pain, Postoperative

Regulation-

Login to view First Approval Timeline

Structure

Molecular FormulaC19H18N2NaO4S

InChIKeyIMBMHWVEMVJSIQ-UHFFFAOYSA-N

CAS Registry198470-85-8

Introduction: This study focuses on the treatment of painful crises in Sickle Cell Disease (SCD) patients using Paracoxib, a non-opioid, compared to Morphine. It addresses the need for alternative medications that reduce opioid dependency while providing effective analgesia.
Objectives:
Primary: Evaluate the analgesic effect of Paracoxib versus Morphine in SCD vaso-occlusive crises.
Secondary: Reduce opioid use/dependence, decrease the length of hospital stays, and monitor side effects related to Paracoxib.
Methodology: A double-blinded randomized controlled trial, conducted in a tertiary care emergency department. The study includes adult SCD patients with moderate to severe crises, excluding non-VOC pain, certain medications, and specific medical conditions. The sample size is 226 patients, split equally into two groups.
Intervention: Patients receive either Morphine or Paracoxib, with periodic assessment of vital signs and pain. Additional Morphine is administered if required. Data collection and analysis are meticulously planned.
Expected Outcomes: Improvement in SCD pain management, reduction in opioid usage, and potential benefits in terms of hospital stays and patient satisfaction.

Start Date01 May 2024

Sponsor / Collaborator

Armed Forces Hospital

ChiCTR2400080886 / SuspendedIIT

To investigate the effect of traditional Chinese medicine five elements music therapy combined with parecoxib on painless induced abortion before operation

Start Date01 Mar 2024

Sponsor / Collaborator-

ChiCTR2400080433 / SuspendedPhase 4IIT

Preoperative application of Parecoxib can alleviate postoperative pain of early esophageal cancer after ESD by reducing inflammatory response

Start Date01 Feb 2024

Sponsor / Collaborator

Shiyan Taihe Hospital

100 Clinical Results associated with Parecoxib Sodium

Login to view more data

100 Translational Medicine associated with Parecoxib Sodium

Login to view more data

100 Patents (Medical) associated with Parecoxib Sodium

Login to view more data

656

Literatures (Medical) associated with Parecoxib Sodium

12 Jan 2024·Organic letters

Iodobenzene-Catalyzed Synthesis of Fully Functionalized NH-Pyrazoles and Isoxazoles from α,β-Unsaturated Hydrazones and Oximes via 1,2-Aryl Shift

Article

Author: Mishra, Bal Krishna ; Tiwari, Bhoopendra ; Singh, Vikram ; Kumar, Deepak

An iodine(III)-catalyzed general method for the synthesis of fully functionalized NH-pyrazoles and isoxazoles from α,β-unsaturated hydrazones and oximes, respectively, via cyclization/1,2-aryl shift/aromatization/detosylation, has been developed. The reaction progresses through an anti-Baldwin 5-endo-trig cyclization. It gives direct access to an advanced intermediate for the preparation of valdecoxib and parecoxib, drugs used for COX-inhibition. In addition, a method for N-alkynylation of pyrazoles has also been developed in the presence of TIPS-EBX.

01 Jan 2024·Journal of orthopaedic surgery (Hong Kong)

Superior analgesic efficacy of preemptive low-dose ketorolac compared with parecoxib after total knee arthroplasty: A retrospective propensity score matching study

Article

Author: Iamthanaporn, Khanin ; Yuenyongviwat, Varah ; Rojjanasirisawat, Nuttawut

Background:

Total knee arthroplasty (TKA) is a routine orthopedic procedure often associated with significant postoperative pain. Efficient pain management is paramount for patient recovery, with nonsteroidal anti-inflammatory drugs (NSAIDs) being a common choice. Nevertheless, the specific NSAID and its dosing regimen can have varying impacts on outcomes.

Methods:

In this retrospective cohort study spanning from January 2016 to December 2020, we analyzed patients who underwent TKA. These patients were divided into two groups: one receiving preemptive low-dose ketorolac (15 mg) followed by 15 mg every 6 h for 48 h, and the other receiving parecoxib (40 mg) every 12 h for the same duration. We assessed pain scores, opioid consumption, and monitored adverse events.

Results:

Our findings reveal that ketorolac yielded superior results compared to parecoxib. Specifically, patients receiving ketorolac reported significantly lower Visual Numeric Rating Scale (VNRS) scores at 8- and 20-h post-surgery. This trend was further confirmed by linear mixed models ( p = .0084). Additionally, ketorolac was associated with reduced opioid consumption during the initial 24 h. Importantly, the rates of adverse events were comparable between the two groups.

Conclusion:

The utilization of preemptive low-dose ketorolac demonstrates promising potential in bolstering pain control within the initial 24 h post-TKA, potentially reducing the need for opioids. However, further exploration is required to thoroughly assess its prolonged analgesic effects and safety across various surgical contexts. These investigations could provide invaluable insights for optimizing pain management protocols.

01 Jan 2024·European review for medical and pharmacological sciences

Effects of parecoxib on postoperative cognitive dysfunction and serum levels of NSE and S100β in elderly patients undergoing surgery.

Article

Author: Yin, W-Y ; Xu, J ; Peng, T ; Li, X ; Liu, X-M ; Guo, B-C ; Fan, C-C

OBJECTIVE:

To investigate the effects of parecoxib on postoperative cognitive dysfunction, and serum levels of neuron-specific enolase (NSE) and S100β protein (S100β) in elderly patients undergoing surgery.

PATIENTS AND METHODS:

The retrospective cohort study method was used to collect the clinical data of 94 elderly patients who underwent elective orthopedic and general anesthesia surgery in our hospital from September 2020 to February 2022. 94 patients were divided into the control group (47 cases) and the study group (47 cases), according to different intervention methods. In the study group, 40 mg of parecoxib was injected intravenously into patients 30 min before the induction of anesthesia, and the patients in the control group were given the same dose of normal saline intravenously before the operation. The basic clinical data of the patients were collected. The levels of the indexes before operation and 6 hours after operation were compared between the two groups, including the Montreal Cognitive Scale (MoCA) score, inflammatory factor indicators [tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP), interleukin-10 (IL-10), interleukin-1β (IL-1β), monocyte chemokine-1 (MCP-1), and inducible nitric oxide synthase (iNOS)], serum cortisol (CORT), beta-amyloid (β-AP), adiponectin (ADP), NSE, and S100β.

RESULTS:

No significant differences in the preoperative MoCA score, TNF-α, IL-6, CRP, IL-10, IL-1β, MCP-1, iNOS, CORT, β-AP, ADP, NSE, and S100β levels were observed between the two groups (p>0.05). The postoperative MoCA score in the study group was significantly higher than that in the control group (p<0.05). The postoperative levels of TNF-α, IL-6, CRP and IL-1β in the study group were significantly lower than those in the control group (p<0.05), and the postoperative levels of IL-10, MCP-1 and iNOS in the study group were significantly higher than those in the control group (p<0.05).

CONCLUSIONS:

Parecoxib can notably inhibit the levels of postoperative inflammatory cytokines, improve neurological dysfunction, and reduce the occurrence of postoperative cognitive dysfunction in patients. The contents of serum NSE and S100β have potential value in the diagnosis of postoperative cognitive dysfunction in elderly patients.

100 Deals associated with Parecoxib Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03717	Parecoxib Sodium	M01AH04	DB08439

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pain, Postoperative	EU	Pfizer Europe MA EEIG	22 Mar 2002
Pain, Postoperative	IS	Pfizer Europe MA EEIG	22 Mar 2002
Pain, Postoperative	LI	Pfizer Europe MA EEIG	22 Mar 2002
Pain, Postoperative	NO	Pfizer Europe MA EEIG	22 Mar 2002

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain	Phase 3	AU	Pfizer Inc.	01 Apr 2003
Colic	Phase 3	IT	Pfizer Inc.	01 Apr 2002
Renal Colic	Phase 3	IT	Pfizer Inc.	01 Apr 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ILCA2020	Not Applicable	Hepatocellular Carcinoma	-	Parecoxib sodium + TAP block	nscmzclqbd(znjpfjxpre) = No significant differences were found between the two groups related to adverse events bzupzcahwt (oqwtflknzc ) View more	Positive	13 Sep 2020
ILCA2020	Phase 3	Hepatocellular Carcinoma	80	Parecoxib sodium 40 mg	meigeerdka(ujjgxdcunu) = uvkdpqmezc xfbvjnnloi (nyloekxvgt, 9.8 - 28.2) View more	Positive	13 Sep 2020
				Placebo	meigeerdka(ujjgxdcunu) = milzuboacl xfbvjnnloi (nyloekxvgt, 8.1 - 19.9) View more
Pubmed \| Anesth Analg	Not Applicable	-	620	Parecoxib	yxceppkdvr(hpclravlrx) = ixdjduapcp hznnymrnue (zwsgcjhkrs, 0.33 - 0.96)	Positive	01 Jun 2017
				Placebo	yxceppkdvr(hpclravlrx) = pdbytmjdxj hznnymrnue (zwsgcjhkrs )
NCT01566669 (PCEA, Pubmed \| J Biol Chem)	Not Applicable	-	240	Parecoxib	qprrylbsqv(rxybeidbxz) = irqyyvuobh vqnlodjszz (brwuguozlg ) View more	Positive	01 Jan 2016
				Placebo	qprrylbsqv(rxybeidbxz) = ckaezbmbra vqnlodjszz (brwuguozlg ) View more
NCT00346268 (PROSTATECTOMY, Pubmed \| BMC Anesthesiol) Manual	Phase 4	Hemorrhage \| Analgesia	105	Morphine+parecoxib	wfpnnclltj(uqskyoysiz) = txmvvxmlkv icjixatnfi (okcpecshvc, 24.1) View more	Positive	09 Mar 2015
				Morphine+Placebo	wfpnnclltj(uqskyoysiz) = vibniazcsj icjixatnfi (okcpecshvc, 28) View more
NCT00553605 (CTgov)	Phase 4	Renal Colic	340	Parecoxib (Parecoxib)	pyvwdqhfkf(cnjculplvq) = gwelkuocer dlguicuoso (vletjrnvqq, ncndebaggy - wxojbfmlvj) View more	-	28 Jan 2013
				Ketoprofen (Ketoprofen)	pyvwdqhfkf(cnjculplvq) = wbbmedxxny dlguicuoso (vletjrnvqq, cvctfqyhka - onvxiftvlw) View more
NCT00346268 (PROSTATECTOMY, CTgov)	Phase 4	Pain, Postoperative	105	Parecoxib+Morphine (Parecoxib and Morphine)	lggecgfytf(xgsykazzap) = taggphbvnn mdujacxima (sqknsonvvk, hfneqhvhwy - wscvksrkff) View more	-	28 Oct 2011
				Placebo+Morphine (Placebo and Morphine)	lggecgfytf(xgsykazzap) = wotqchplyk mdujacxima (sqknsonvvk, zcvcmozkqd - nxtxqyluxf) View more
NCT00455117 (Pubmed \| Vet Anaesth Analg)	Phase 4	Pain	-	Parecoxib 40 mg	kxoavuksiz(tdnkleszwg) = cbnyksuouf mblndansux (ttzlylpczy )	Negative	01 Sep 2011
				Placebo	kxoavuksiz(tdnkleszwg) = rjyqhyygzz mblndansux (ttzlylpczy )
NCT03915561 (Pubmed \| Anesth Analg)	Phase 2	-	-	Parecoxib	romxbnysiw(myqkimhxhq) = bvskmyejuc mjvkntunqn (fxfmhgzcsy )	Negative	01 Jan 2009
				Placebo	romxbnysiw(myqkimhxhq) = kppbwotoub mjvkntunqn (fxfmhgzcsy )